Predictive value of indirect bilirubin before neoadjuvant chemoradiotherapy in evaluating prognosis of local advanced rectal cancer patients

Table 1 Clinical characteristics and treatment strategies of local advanced rectal cancer patients

Characteristic	Pre-IBIL ≤ 6.2 μmol/L (n = 163)	Pre-IBIL > 6.2 μmol/L (n = 161)	P value	All patients (n = 324)
Age, yr			0.305
< 60	88 (53.99)	97 (60.25)		185 (57.10)
≥ 60	75 (46.01)	64 (39.75)		139 (42.90)
Sex			0.007
Female	61 (37.42)	37 (22.98)		98 (30.25)
Male	102 (62.58)	124 (77.02)		226 (69.75)
BMI, kg/m2			0.317
< 18.5	7 (4.29)	4 (2.48)		11 (3.40)
18.5-23.9	86 (52.76)	73 (45.34)		159 (49.07)
24.0-27.9	52 (31.90)	66 (40.99)		118 (36.42)
≥ 28.0	18 (11.04)	18 (11.18)		36 (11.11)
Smoking history			0.581
No	87 (53.37)	80 (49.69)		167 (51.54)
Yes	76 (46.63)	81 (50.31)		157 (48.46)
Drinking history			0.925
No	96 (58.90)	93 (57.76)		189 (58.33)
Yes	67 (41.10)	68 (42.24)		135 (41.67)
Chronic disease history			0.624
No	100 (61.35)	104 (64.60)		204 (62.96)
Yes	63 (38.65)	57 (35.40)		120 (37.04)
cTNM stage			0.839
II	23 (14.11)	25 (15.53)		48 (14.81)
III	140 (85.89)	136 (84.47)		276 (85.19)
nCRT with surgery interval, d			0.573
31-60	88 (53.99)	79 (49.07)		167 (51.54)
61-90	63 (38.65)	66 (40.99)		129 (39.81)
> 90	12 (7.36)	16 (9.94)		28 (8.64)
Inferior margin			0.373
≤ 5 cm	109 (66.87)	116 (72.05)		225 (69.44)
> 5 cm	54 (33.13)	45 (27.95)		99 (30.56)
TRG			0.160
1	14 (8.59)	16 (9.94)		30 (9.26)
2	90 (55.21)	72 (44.72)		162 (50.00)
3	41 (25.15)	43 (26.71)		84 (25.93)
4	18 (11.04)	30 (18.63)		48 (14.81)
Vascular invasion			0.471
Negative	155 (95.09)	149 (92.55)		304 (93.83)
Positive	8 (4.91)	12 (7.45)		20 (6.17)
Neural invasion			0.846
Negative	130 (79.75)	126 (78.26)		256 (79.01)
Positive	33 (20.25)	35 (21.74)		68 (20.99)
Radiotherapy type before surgery			0.688
VMAT	146 (89.57)	140 (86.96)		286 (88.27)
IMRT	14 (8.59)	16 (9.94)		30 (9.26)
3D-CRT	3 (1.84)	5 (3.11)		8 (2.47)
Chemotherapy type before surgery			0.975
Capecitabine	145 (88.96)	144 (89.44)		289 (89.20)
Capecitabine + platinum	9 (5.52)	9 (5.59)		18 (5.56)
Other	9 (5.52)	8 (4.97)		17 (5.25)
Adjuvant chemotherapy			0.383
No	57 (34.97)	48 (29.81)		105 (32.41)
Yes	106 (65.03)	113 (70.19)		219 (67.59)
Pre-CEA			0.832
≤ 5 ng/mL	91 (55.83)	87 (54.04)		178 (54.94)
> 5 ng/mL	72 (44.17)	74 (45.96)		146 (45.06)
Pre-CA19-9			0.931
≤ 27 U/mL	131 (80.37)	131 (81.37)		262 (80.86)
> 27 U/mL	32 (19.63)	30 (18.63)		62 (19.14)

nCRT: Neoadjuvant chemoradiotherapy; pre-IBIL: Indirect bilirubin before neoadjuvant chemoradiotherapy; BMI: Body mass index; TRG: Tumor regression grade; VMAT: Volumetric modulated arc therapy; IMRT: Intensity modulated radiation therapy; 3D-CRT: 3-dimensional conformal radiation therapy; pre-CEA: Carcinoembryonic antigen before neoadjuvant chemoradiotherapy; pre-CA19-9: Carbohydrate antigen 19-9 before neoadjuvant chemoradiotherapy.